Evidence map›Paper›PMID 40512359›Full record

ArticleCurrent medical science2025

Rifaximin Inhibits Small Bowel Angiodysplasia-Associated Angiogenesis by Attenuating LncRNA-HIF1A-AS2/miR-153-3p/HIF-1 α/Ang-2 Axis.

Shuai Peng, An-Ning Yin, Fei Liao, Liang Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shuai Peng *Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
An-Ning Yin *Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Fei LiaoDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Liang ZhaoDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. airmanzhao@whu.edu.cn.

Funding

Natural Science Foundation of Hubei Province 2022CFC010
6 · The paper itself

Abstract

BACKGROUNDS AND

objectiveAngiopoietin-2 (Ang-2) is a promising biomarker and therapeutic target for gastrointestinal angiodysplasia (GIAD). We hypothesized that the lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 axis plays a critical role in small bowel angiodysplasia (SBAD)-associated angiogenesis, which can be blocked by rifaximin. The purpose of this study was to investigate the expression and pro-angiogenic effects of the lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 in SBAD and to evaluate the therapeutic potential of rifaximin on SBAD by targeting this axis.

methodsThe expression and pro-angiogenic effects of lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 were analysed in SBAD tissues and human umbilical vein endothelial cells (HUVECs). The anti-angiogenic effect of rifaximin and its impact on the lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 axis were evaluated in HUVECs.

resultsIncreased expression of lncRNA-HIF1A-AS2 and decreased expression of miR-153-3p were detected in SBAD tissues. LncRNA-HIF1A-AS2/miR-153-3p /HIF-1α were upstream regulators of Ang-2, and this axis was involved in angiogenesis in HUVECs. Rifaximin exerted antiangiogenic effects on HUVECs by blocking this axis.

conclusionsThe lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 axis is critically involved in SBAD-associated angiogenesis. Rifaximin is a potential therapeutic option for SBAD via blockade of this axis.

Indexed as

AngiodysplasiaAngiopoietin-2Hypoxia-Inducible Factor 1, alpha SubunitIntestine, SmallMicroRNAsNeovascularization, PathologicRifaximinRNA, Long NoncodingAngiogenesisFemaleHumansHuman Umbilical Vein Endothelial CellsMaleMiddle AgedAngiopoietin-2ANGPT2 protein, humanHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitMicroRNAsMIRN153 microRNA, humanRifaximinRNA, Long NoncodingGastrointestinal angiodysplasiaLncRNA-HIF1A-AS2RifaximinSmall bowel

Identifiers

PMID40512359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.